Baxter Intl Inc Stock Price, News & Analysis

Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the Raymond James & Associates' 46th Annual Institutional Investors Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Monday, March 3, 2025, at 1:05 p.m. Eastern Time.

Interested parties can access the live webcast of the presentation through www.baxter.com. The presentation recording will remain available for replay until August 30, 2025.

Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the upcoming Citi - 2025 Medtech & Life Sciences Access Day. Joel Grade, Baxter's chief financial officer, will deliver a presentation on Thursday, February 27, 2025, at 1:00 p.m. Eastern Time.

The presentation will be accessible through a live webcast on www.baxter.com. For those unable to attend the live session, a replay will remain available until Tuesday, August 26, 2025.

Baxter International (NYSE:BAX) has announced a quarterly cash dividend declaration by its Board of Directors. The company will pay $0.17 per share of common stock, with an indicated annual dividend rate of $0.68 per share. The dividend will be distributed on April 1, 2025, to stockholders of record as of February 28, 2025.

Baxter International (NYSE:BAX) announced the immediate retirement of José (Joe) E. Almeida from his positions as Chair, President, and CEO. Lead Independent Director Brent Shafer has been appointed as Chair and Interim CEO, with the board initiating a comprehensive search for a permanent CEO.

The company also appointed Heather Knight as Executive Vice President and Chief Operating Officer, responsible for global operations including sales, marketing, R&D, supply chain, and medical affairs. Nancy Schlichting will assume the role of lead independent director.

Baxter recently completed the sale of its Kidney Care business to Carlyle on January 31, 2025. The company expects Q4 and full-year 2024 results to align with previous guidance, maintaining its 2025 objectives of 4-5% operational sales growth and approximately 16.5% adjusted operating margin. However, these projections don't include potential impacts from recently announced U.S. tariffs on imports from Mexico, Canada, and China.

Baxter International (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. Investors can pre-register for the call through a provided registration link. The conference call will also be accessible via webcast through Baxter's website. The company notes that the call will be recorded and is copyrighted material, requiring Baxter's permission for any recording or rebroadcasting.

Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's chair, president and chief executive officer, José (Joe) E. Almeida, will deliver a presentation on Monday, January 13, 2025, at 10:30 a.m. Pacific Time. Interested parties can access the live webcast through www.baxter.com, with replay availability extending until July 12, 2025.

Baxter International (NYSE:BAX) announced five new injectable pharmaceutical product launches in the U.S., bringing their total launches to 10 in 2024. The new products include: Micafungin for Candida infections, Cyclophosphamide Injection for malignant diseases, Pantoprazole Sodium for GERD treatment, Cefazolin in a new 3g/150mL strength for various infections, and Levetiracetam for seizure treatment.

These ready-to-use formats utilize Baxter's proprietary container technology and are designed to improve operational efficiencies, simplify medication preparation, and enhance patient safety by reducing contamination risks and potential compounding errors.

Baxter International (NYSE:BAX) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Thursday, December 5, 2024, at 9:10 a.m. Eastern Time. The presentation will be accessible via live webcast on www.baxter.com and will remain available for replay until Tuesday, June 3, 2025.

Baxter International (NYSE:BAX) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Wednesday, November 20, 2024, at 11:00 a.m. GMT. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 19, 2025.